MedTrace Logo

Safety Study of Apixaban in Recent Acute Coronary Syndrome

NCT00313300 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1741

Last updated 2015-12-30

Study results available
· View outcomes & findings →

Summary

The purpose of this clinical research study is to determine whether apixaban will be safe in people who have recently had unstable angina or a heart attack.

Conditions

  • Acute Coronary Syndrome (ACS)

Interventions

DRUG

Apixaban

Tablets, Oral, 2.5 mg, twice daily, 26 weeks

DRUG

Apixaban

Tablets, Oral, 10 mg, once daily, 26 weeks

DRUG

Placebo

Tablets, Oral, 0, twice daily, 26 weeks

DRUG

Apixaban

Tablets, Oral 10 mg, twice daily, 26 weeks

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2008-05-31
Completion
2008-05-31

Countries

  • United States
  • Austria
  • Belgium
  • Canada
  • Denmark
  • France
  • Germany
  • Israel
  • Italy
  • Poland
  • Russia
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00313300 on ClinicalTrials.gov